Home › Trials › NCT06635148

Long-term safety assessment of JNJ-81201887 for eye condition related to aging

Long-term Extension Study for Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies

Phase 2 Interventional Janssen Research & Development, LLC · NCT06635148

This study is testing the long-term safety of a new eye treatment for age-related vision loss in people who have already tried it before.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment274 (estimated)
Ages60 Years and up
SexAll
SponsorJanssen Research & Development, LLC Industry-sponsored
Locations104 sites (Tucson, Arizona and 103 other locations)
Trial IDNCT06635148 on ClinicalTrials.gov

What this trial studies

This study evaluates the long-term safety and tolerability of JNJ-81201887, an investigational treatment administered via intravitreal injection, in participants who previously received this treatment or a sham in earlier clinical studies. The study aims to gather data on the effects of the treatment over an extended period. Participants will be monitored for any adverse effects and overall health outcomes related to geographic atrophy secondary to age-related macular degeneration.

Who should consider this trial

Good fit: Ideal candidates are individuals who have previously participated in parent studies and received treatment with JNJ-81201887 or a sham procedure.

Not a fit: Patients who have not participated in the parent studies will not benefit from this long-term extension study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the long-term safety of a new treatment for patients with geographic atrophy.

How similar studies have performed: Other studies involving similar treatments for age-related macular degeneration have shown promising results, indicating potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Participants who were enrolled and received treatment with JNJ-81201887 or sham in a parent clinical study (81201887MDG2001, 81201887MDG1003)
* Females (women of childbearing potential), male participants, and partners of male participants will not be required to use contraception in this LTE study
* Must sign an informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study. The ICF may be signed by an impartial witness and/or legally designated representative depending on national/local regulations

Exclusion Criteria:

* There are no exclusion criteria for this LTE study

Where this trial is running

Tucson, Arizona and 103 other locations

+54 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Geographic AtrophyMacular Degeneration
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.